Angiotech completes Neucoll merger:
This article was originally published in Clinica
Angiotech Pharmaceuticals has completed its acquisition of Neucoll, a privately-held orthobiologics company based in Los Gatos, California. Vancouver, Canada-based Angiotech first announced its intention to acquire all the share capital of Neucoll in July (see Clinica No 1114, p 13) as part of its strategy to build up its orthopaedics business. With this $13m all-cash transaction, Angiotech has bought Neucoll's two key products, the Collagraft and Neugraft bone graft matrixes.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.